A carregar...
Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(®)) in hemophilia A
rFVIIIFc (efraloctocog alfa, Eloctate(®)) is an extended half-life (EHL) factor VIII licensed for use in patients with hemophilia A for prophylaxis and treatment of bleeding and surgical episodes. Pharmacokinetic studies in adults have shown a mean 1.5-fold increase in half-life compared to full-len...
Na minha lista:
| Publicado no: | J Blood Med |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5028163/ https://ncbi.nlm.nih.gov/pubmed/27695377 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S80814 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|